NEW YORK, Jan. 13 (GenomeWeb News) - Alnylam Pharmaceuticals has licensed RNA interference patents to Invitrogen, Cell Signaling Technology, and Cenix Bioscience, the company said today.
Invitrogen, headquartered in Carlsbad, Calif., has obtained a license to provide research products and services under a patent family owned by Alnylam that covers the use of short double-stranded RNAs to mediate RNAi and that includes European patent 1 144 623.
Cell Signaling Technology, located in Beverly, Mass., has licensed one RNAi patent to provide research products. Following an initial payment, the company will pay Alnylam annual fees and royalties on product sales.
Cenix BioScience, of Dresden, Germany, has licensed one RNAi patent to market its RNAi research services. It will pay Alnylam annual fees and royalties on the services it provides. In addition, Cenix will provide Alnylam with its expertise in designing and testing small interfering RNAs.
The licenses were granted by Ribopharma of Kulmbach, Germany, one of Alnylam's two operating units.